Dominic Eisinger, PhD
Chair, Alternative Investments Sub-Committee
Town of Residence: Keene, NY
Dominic Eisinger, PhD, is a biotechnology executive and entrepreneur who combines his scientific expertise with business insights to achieve sustained commercial impact and value.
In his current role at Myriad RBM (a subsidiary of Myriad Genetics), Dr. Eisinger leads global sales, marketing, customer support, new product development, and partnership strategies to position the company as a top provider of protein biomarker testing services for drug development clinical trials. He is the company’s lead scientific speaker on pharmacodynamic protein biomarker research in oncology, inflammation, cardiovascular, kidney, and autoimmune disease therapies.
Dr. Eisinger’s commercial success is grounded in his experiences as an entrepreneur. He co-founded, raised capital, and built Multiplex Biosciences, a contract research laboratory in Lake Placid, New York, which was acquired by RBM in 2006. Prior to that, he started and grew a business within a business at Upstate Cell Signaling Solutions, helping the company enter a new market and develop a reputation for innovation.
Dr. Eisinger previously served on the Board of the UVMHN-Elizabethtown Community Hospital for nine years, including three years as Vice Chair and two years as Chair. Over this period, the hospital more than doubled its revenue and profitability, quadrupled the number of remote primary care clinics, and expanded or renovated all of its facilities.
Dr. Eisinger earned a Bachelor of Science from Cornell University and his PhD from the University of Vermont, prior to completing post-doctoral training at Dartmouth Medical School